KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma

Amandine Decroos; Morgane Cheminant; Julie Bruneau; Sylvain Carras; Vincent Parinet; Laura Pelletier; Laetitia Lacroix; Nadine Martin; Jérôme Giustiniani; Ludovic Lhermitte; Vahid Asnafi; Maxime Battistella; François Lemonnier; Laurence De Leval; Hélène Sicard; Cécile Bonnafous; Laurent Gauthier; Laurent Genestier; Stefano Caruso; Philippe Gaulard; Olivier Hermine; Nicolas Ortonne

doi:10.3324/haematol.2022.282220

KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma

Haematologica. 2023 Oct 1;108(10):2830-2836. doi: 10.3324/haematol.2022.282220.

Authors

Amandine Decroos¹, Morgane Cheminant², Julie Bruneau³, Sylvain Carras⁴, Vincent Parinet¹, Laura Pelletier¹, Laetitia Lacroix⁵, Nadine Martin¹, Jérôme Giustiniani¹, Ludovic Lhermitte⁶, Vahid Asnafi⁶, Maxime Battistella⁷, François Lemonnier⁸, Laurence De Leval⁹, Hélène Sicard¹⁰, Cécile Bonnafous¹⁰, Laurent Gauthier¹⁰, Laurent Genestier¹¹, Stefano Caruso¹², Philippe Gaulard¹³, Olivier Hermine², Nicolas Ortonne¹⁴

Affiliations

¹ Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil.
² Université de Paris, Institut Imagine, Laboratory of Hematological Disorders, INSERM UMR1163, F-75015, Paris, France; Necker-Enfants Malades University Medical Center, AP-HP Clinical Hematology, F-75015, Paris.
³ Université de Paris, Institut Imagine, Laboratory of Hematological Disorders, INSERM UMR1163, F-75015, Paris, France; Necker-Enfants Malades University Medical Center, AP-HP, Department of Pathology, F-75015, Paris.
⁴ Institute for Advanced Biosciences, "Translational Epigenetics" team, UMR 1209/CNRS 5309, La Tronche.
⁵ Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil, France; Université de Paris, Institut Imagine, Laboratory of Hematological Disorders, INSERM UMR1163, F-75015, Paris.
⁶ Université de Paris, Institut Necker-Enfants Malades, Laboratory of Onco-Hematology, APHP, INSERM UMR 1151, Paris.
⁷ Université Paris Cité ; INSERM U976 ; AP-HP, Department of Pathology, Saint-Louis hospital, F-75010 Paris.
⁸ Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil, France; Henri Mondor hospital, Clinical Hematology, Unité Hémopathies Lymphoïdes, AP-HP, F-94010, Créteil.
⁹ Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University.
¹⁰ Innate Pharma, Marseille, F-13009.
¹¹ Claude Bernard Lyon 1 University, ENS de Lyon, CNRS, UMR5308, INSERM U1111, CIRI, Centre International de Recherche en Infectiologie, Lymphoma Immunobiology Team (LIB), Equipe Labellisée Ligue Contre le Cancer, F-69007, Lyon, France; Hospices Civils de Lyon, Lyon.
¹² Henri Mondor hospital, AP-HP, Department of Pathology, F-94010, Créteil.
¹³ Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil, France; Henri Mondor hospital, AP-HP, Department of Pathology, F-94010, Créteil.
¹⁴ Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil, France; Henri Mondor hospital, AP-HP, Department of Pathology, F-94010, Créteil. nicolas.ortonne@aphp.fr.

No abstract available

Publication types

Letter

MeSH terms

Humans
Lymphoma, T-Cell, Cutaneous*
Lymphoma, T-Cell, Peripheral* / drug therapy
Lymphoma, T-Cell, Peripheral* / genetics
Receptors, KIR3DL2
Skin Neoplasms* / drug therapy

Substances

Receptors, KIR3DL2
KIR3DL2 protein, human

Grants and funding

Funding: This study was financially supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), Innate Pharma (Marseille, France), and the Institut National du Cancer (INCa). AD is the recipient of a grant from Innate Pharma and MC is the recipient of INCa.